Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Arlett

Showing results (1-10 of 57) with videos related to

Pageof 6
Sort By:
British Journal of Clinical Pharmacology|February 18, 2020
Measuring the impact of risk communications: Robust analytical approaches are keyPeter Arlett
Drug Safety|January 15, 2019
Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety SurveillancePeter Arlett
Expert Review of Clinical Pharmacology|November 6, 2012
Pharmacovigilance in Europe: direction of travel in a changing environmentAna Hidalgo-Simon, Peter Arlett
BMJ (Clinical Research Ed.)|April 3, 2023
RCTs and real world evidence are complementary, not alternativesDaniel R Morales, Peter Arlett
Clinical Pharmacology and Therapeutics|November 24, 2019
Pharmacovigilance 2030: Invited Commentary for the January 2020 "Futures" Edition of Clinical Pharmacology and TherapeuticsPeter Arlett, Sabine Straus, Guido Rasi
Clinical Pharmacology and Therapeutics|April 11, 2019
Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for EuropeAlison Cave, Xavier Kurz, Peter Arlett
Nature Reviews. Drug Discovery|May 29, 2026
Better data for better medicines: a path to data-driven medicines regulationFrancois Domergue, Peter Arlett, Emer Cooke, et al.
Clinical Pharmacology and Therapeutics|November 19, 2021
Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing ValuePeter Arlett, Jesper Kjaer, Karl Broich, et al.
Clinical Pharmacology and Therapeutics|August 29, 2020
International Collaboration in Real-World Evidence Generation for Direct Acting Oral Anti-CoagulantsPeter Arlett, Xavier Kurz, Katherine Soltys, et al.
British Journal of Clinical Pharmacology|June 22, 2023
European Medicines Agency seeks stakeholders' views on future transparency measures for clinical trialsRosa Gonzalez-Quevedo, Laura Pioppo, Juan Garcia Burgos, et al.
Pageof 6

Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
British Journal of Clinical Pharmacology|February 18, 2020
Measuring the impact of risk communications: Robust analytical approaches are keyPeter Arlett
Drug Safety|January 15, 2019
Building an Evidence Base on the Place of Industry-Sponsored Programs in Drug Safety SurveillancePeter Arlett
Expert Review of Clinical Pharmacology|November 6, 2012
Pharmacovigilance in Europe: direction of travel in a changing environmentAna Hidalgo-Simon, Peter Arlett
BMJ (Clinical Research Ed.)|April 3, 2023
RCTs and real world evidence are complementary, not alternativesDaniel R Morales, Peter Arlett
Clinical Pharmacology and Therapeutics|November 24, 2019
Pharmacovigilance 2030: Invited Commentary for the January 2020 "Futures" Edition of Clinical Pharmacology and TherapeuticsPeter Arlett, Sabine Straus, Guido Rasi
Clinical Pharmacology and Therapeutics|April 11, 2019
Real-World Data for Regulatory Decision Making: Challenges and Possible Solutions for EuropeAlison Cave, Xavier Kurz, Peter Arlett
Nature Reviews. Drug Discovery|May 29, 2026
Better data for better medicines: a path to data-driven medicines regulationFrancois Domergue, Peter Arlett, Emer Cooke, et al.
Clinical Pharmacology and Therapeutics|November 19, 2021
Real-World Evidence in EU Medicines Regulation: Enabling Use and Establishing ValuePeter Arlett, Jesper Kjaer, Karl Broich, et al.
Clinical Pharmacology and Therapeutics|August 29, 2020
International Collaboration in Real-World Evidence Generation for Direct Acting Oral Anti-CoagulantsPeter Arlett, Xavier Kurz, Katherine Soltys, et al.
British Journal of Clinical Pharmacology|June 22, 2023
European Medicines Agency seeks stakeholders' views on future transparency measures for clinical trialsRosa Gonzalez-Quevedo, Laura Pioppo, Juan Garcia Burgos, et al.
Pageof 6